Analysts See $1.76 EPS for Express Scripts Holding Company (ESRX); 2 Analysts Covering Meridian Bioscience, Inc. (VIVO)

April 25, 2018 - By Linda Rogers

Meridian Bioscience, Inc. (NASDAQ:VIVO) Logo

Among 5 analysts covering Meridian Bioscience (NASDAQ:VIVO), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. Meridian Bioscience had 13 analyst reports since July 28, 2015 according to SRatingsIntel. As per Thursday, September 10, the company rating was maintained by Canaccord Genuity. The stock of Meridian Bioscience, Inc. (NASDAQ:VIVO) has “Neutral” rating given on Monday, March 21 by Hilliard Lyons. The stock of Meridian Bioscience, Inc. (NASDAQ:VIVO) earned “Hold” rating by Robert W. Baird on Thursday, October 19. The stock of Meridian Bioscience, Inc. (NASDAQ:VIVO) earned “Sell” rating by Piper Jaffray on Thursday, September 21. The rating was maintained by Piper Jaffray with “Sell” on Thursday, July 27. As per Thursday, January 25, the company rating was maintained by Piper Jaffray. As per Thursday, January 25, the company rating was maintained by Robert W. Baird. The stock of Meridian Bioscience, Inc. (NASDAQ:VIVO) has “Sell” rating given on Thursday, October 19 by Piper Jaffray. Canaccord Genuity maintained it with “Hold” rating and $16.0 target in Thursday, January 25 report. The rating was upgraded by Hilliard Lyons on Monday, March 28 to “Buy”. See Meridian Bioscience, Inc. (NASDAQ:VIVO) latest ratings:

25/01/2018 Broker: Piper Jaffray Rating: Sell New Target: $11.0 Maintain
25/01/2018 Broker: Canaccord Genuity Rating: Hold New Target: $16.0 Maintain
25/01/2018 Broker: Robert W. Baird Rating: Hold New Target: $16.0 Maintain

Analysts expect Express Scripts Holding Company (NASDAQ:ESRX) to report $1.76 EPS on May, 2 after the close.They anticipate $0.43 EPS change or 32.33% from last quarter’s $1.33 EPS. ESRX’s profit would be $988.30 million giving it 10.72 P/E if the $1.76 EPS is correct. After having $2.16 EPS previously, Express Scripts Holding Company’s analysts see -18.52% EPS growth. The stock increased 0.40% or $0.3 during the last trading session, reaching $75.49. About 2.09M shares traded. Express Scripts Holding Company (NASDAQ:ESRX) has risen 8.93% since April 25, 2017 and is uptrending. It has underperformed by 2.62% the S&P500.

Investors sentiment decreased to 1.2 in 2017 Q4. Its down 0.17, from 1.37 in 2017Q3. It turned negative, as 21 investors sold Meridian Bioscience, Inc. shares while 44 reduced holdings. 31 funds opened positions while 47 raised stakes. 36.52 million shares or 0.72% more from 36.26 million shares in 2017Q3 were reported. Tower Research Cap Ltd Liability Co (Trc) reported 0.01% stake. Pnc Financial Svcs Group Incorporated holds 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO) or 116,538 shares. State Of New Jersey Common Pension Fund D has 0% invested in Meridian Bioscience, Inc. (NASDAQ:VIVO). Legal & General Group Inc Public Limited Com holds 0% or 87,493 shares. Millennium Mngmt Ltd Liability Corp has 0.02% invested in Meridian Bioscience, Inc. (NASDAQ:VIVO). Tudor Corp Et Al reported 46,042 shares. Vanguard Group Incorporated reported 4.20M shares. Schroder Inv Group holds 0% or 48,947 shares. Jpmorgan Chase reported 623,331 shares. Gsa Capital Prtnrs Limited Liability Partnership stated it has 0.08% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Fuller & Thaler Asset Mngmt Incorporated, California-based fund reported 1,650 shares. 16,290 are held by Johnson Counsel Incorporated. Us Commercial Bank De holds 3,566 shares or 0% of its portfolio. Prudential Financial, New Jersey-based fund reported 376,224 shares. Menta Limited Company accumulated 22,678 shares.

The stock decreased 1.04% or $0.15 during the last trading session, reaching $14.3. About 165,954 shares traded. Meridian Bioscience, Inc. (NASDAQ:VIVO) has risen 7.87% since April 25, 2017 and is uptrending. It has underperformed by 3.68% the S&P500.

Meridian Bioscience, Inc., a life science company, develops, makes, distributes, and sells diagnostic test kits primarily for various gastrointestinal, viral, respiratory, and parasitic infectious diseases worldwide. The company has market cap of $605.00 million. The firm operates through Diagnostics and Life Science divisions. It has a 28.04 P/E ratio. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the illumigene brand; rapid immunoassays, a single-use immunoassays that can be used in point-of-care settings under the TRU, ImmunoCard, and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the Premier brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand.

Since February 7, 2018, it had 2 insider purchases, and 0 insider sales for $28,784 activity. Rice John McCune Jr. bought $14,750 worth of stock or 1,000 shares. McIlwraith John had bought 1,000 shares worth $14,034.

Investors sentiment increased to 0.69 in 2017 Q4. Its up 0.07, from 0.62 in 2017Q3. It is positive, as 68 investors sold Express Scripts Holding Company shares while 407 reduced holdings. 111 funds opened positions while 216 raised stakes. 479.40 million shares or 1.52% less from 486.80 million shares in 2017Q3 were reported. Baker Ellis Asset Management Lc has invested 0.03% in Express Scripts Holding Company (NASDAQ:ESRX). Usa Financial Portformulas Corporation owns 4,872 shares or 0.09% of their US portfolio. Savant Cap Ltd Liability stated it has 3,144 shares or 0.05% of all its holdings. Moreover, Cape Cod Five Cents Comml Bank has 0.04% invested in Express Scripts Holding Company (NASDAQ:ESRX) for 3,598 shares. Leavell reported 0.03% in Express Scripts Holding Company (NASDAQ:ESRX). Guardian Life Company Of America has invested 0.03% in Express Scripts Holding Company (NASDAQ:ESRX). Klingenstein Fields Limited Co has invested 0.08% in Express Scripts Holding Company (NASDAQ:ESRX). Eqis Cap Mgmt has 0.08% invested in Express Scripts Holding Company (NASDAQ:ESRX). Moreover, Stevens Cap Management Limited Partnership has 0.13% invested in Express Scripts Holding Company (NASDAQ:ESRX). Financial Bank Of Nova Scotia owns 393,350 shares for 0.13% of their portfolio. Ironwood Counsel Lc accumulated 5,187 shares. Hl Svcs Ltd Co holds 20,362 shares or 0.03% of its portfolio. Td Asset Mngmt invested in 0.03% or 262,216 shares. Geode Capital Mngmt Limited Liability Com reported 6.61 million shares. Riverhead Capital Mgmt Ltd Liability Corp holds 0.71% or 223,568 shares in its portfolio.

Express Scripts Holding Company operates as a pharmacy benefit management firm in the United States, Canada, and Europe. The company has market cap of $42.39 billion. It operates in two divisions, PBM and Other Business Operations. It has a 9.75 P/E ratio. The PBM segment offers clinical solutions, specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, administration of a group purchasing organization, and consumer health and drug information services.

Among 25 analysts covering Express Scripts (NASDAQ:ESRX), 8 have Buy rating, 3 Sell and 14 Hold. Therefore 32% are positive. Express Scripts had 66 analyst reports since July 30, 2015 according to SRatingsIntel. RBC Capital Markets maintained it with “Outperform” rating and $96 target in Thursday, July 30 report. Bernstein initiated Express Scripts Holding Company (NASDAQ:ESRX) on Thursday, June 16 with “Underperform” rating. The stock of Express Scripts Holding Company (NASDAQ:ESRX) has “Buy” rating given on Thursday, December 14 by SunTrust. The firm has “Buy” rating given on Thursday, June 8 by Cowen & Co. The company was upgraded on Friday, November 4 by Deutsche Bank. The rating was upgraded by Cowen & Co to “Outperform” on Monday, April 4. The rating was initiated by UBS with “Neutral” on Thursday, October 6. Jefferies maintained the stock with “Buy” rating in Friday, December 15 report. Maxim Group maintained Express Scripts Holding Company (NASDAQ:ESRX) on Tuesday, July 18 with “Buy” rating. The stock has “Buy” rating by SunTrust on Thursday, January 11.

Express Scripts Holding Company (NASDAQ:ESRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: